Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioCentury
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioCentury
-
GSK to provide adjuvant to boost effectiveness and stretch supplies of
#2019nCoV vaccines$GSKhttps://buff.ly/395UWSPHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
Well that’s a wrap on Europe for the UK (
). But UK biotech still wants to tango. We‘ve got the companies, you’ve got the regulators- let’s dance. @StephenPHansen with the story, in@BioCentury.https://www.biocentury.com/article/304340Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It's been a bad year for abuse-deterrent opioids. Here's what that means for the drug class, and how the path forward might look.https://buff.ly/2GEQmyG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A study from NCI's Steve Rosenberg suggests the solid tumor-fighting powers of TILs could also be sourced from blood.https://buff.ly/37N1Jk1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@karolinskainst,@institutpasteur,@UCSanDiego demonstrate how a cell-based fluorescence assay can be used in drug discovery to predict the potency of compounds that allosterically modulate transcription factor dimerizationhttps://buff.ly/2RPD7lfHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
An overview from
@StephenPHansen on how@BioNTech_Group is deciding which technologies to apply to different cancer settingshttps://buff.ly/2OimjkoHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EMA's CHMP recommended a basket of therapies including Alnylam's RNAi therapeutic Givlaari, Novo's oral diabetes treatment Rybelsus, Esperion's bempedoic acid alone and in combination, and more
$ALNY;$NVO$ESPRhttps://buff.ly/2te7Iz8Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reata had double-digit gains Friday after Amgen revealed interest in renal opportunities on earnings call. The pharma itself dipped due to lower-than-expected FY20 guidance
$RETA$AMGNhttps://buff.ly/2uS6hqNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cardior's preclinical POC data for its first clinical candidate shows the miR-132 inhibitor goes beyond treating the cardiovascular symptoms of
#HeartFfailure to reverse established disease in animal modelshttps://buff.ly/2S8ZssBHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury's preclinical roundup includes CEPI funding for CureVac on 2019-nCoV
#coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI$IBMhttps://buff.ly/2RMElh2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wuhan, the epicenter of the
#coronavirus outbreak, is home to a large chunk of China's clinical trials.https://buff.ly/37MnC2ZHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury's latest roundup of management moves includes a trio of women appointed to C-suite positions; plus an FDA director retires, and morehttps://buff.ly/2S5pCws
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dermatology company Arcutis made its public debut, raising $159 million. The biotech is the third to close a NASDAQ IPO this year
$ARQT$BDTX$IMABhttps://buff.ly/36LT5RtHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy Palforzia
$AIMThttps://buff.ly/2GHnBRRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What Exscientia and Sumitomo Dainippon's trial launch does and doesn't say about AI's potential in drug development.https://buff.ly/37O6CJo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in
@BioCentury. Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.https://www.biocentury.com/biocentury/targets-mechanisms/2020-01-24/targets-and-indications-car-t-developers-are-exploring--0 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
U.S. declares #2019-nCoV public health emergency. Separate declarations will be needed if FDA is going to issue Emergency Use Authorizations for use of unapproved diagnostics, drugs or vaccines.https://buff.ly/2RJpXWK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With
#Brexit complete, the British biotech sector is focused on close regulatory cooperation with EMA and access to global talent as top priorities for coming trade negotations,@BIA_UK Steve Bates tells@BioCenturyhttps://buff.ly/2GFsNpmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CSL's logistics capabilities could give it a leg up as the company expands into cell and gene therapyhttps://buff.ly/2GFAawW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.